c-Kit (d557-558)

KIT · Variant type: indel · HGVS: p.557_558del

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Avapritinib	98.2%	1.8%	97.73
2	Tivozanib	98.0%	2.0%	92.42
3	Pacritinib	97.5%	2.5%	88.64
4	Ripretinib	97.2%	2.8%	92.95
5	Erdafitinib	96.5%	3.5%	95.71
6	Brigatinib	96.0%	4.0%	82.96
7	Dasatinib	95.9%	4.1%	87.97
8	Ponatinib	95.2%	4.8%	78.23
9	Nintedanib	95.0%	5.0%	90.23
10	Pralsetinib	94.4%	5.6%	93.43
11	Cabozantinib	94.3%	5.7%	92.73
12	Apatinib	93.9%	6.1%	97.73
13	Selpercatinib	93.7%	6.3%	96.72
14	Sorafenib	92.9%	7.1%	96.72
15	Fostamatinib	92.7%	7.3%	96.74
16	Nilotinib	92.6%	7.4%	96.49
17	Imatinib	92.1%	7.9%	99.00
18	Axitinib	91.9%	8.1%	93.23
19	Umbralisib	91.5%	8.5%	98.74
20	Quizartinib	91.4%	8.6%	99.50
21	Regorafenib	89.8%	10.2%	95.99
22	Sunitinib	89.3%	10.7%	91.73
23	Fedratinib	89.2%	10.8%	96.21
24	Gilteritinib	89.1%	10.9%	88.97
25	Pazopanib	88.9%	11.1%	97.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Avapritinib	98.2%	—	—
Tivozanib	98.0%	—	—
Pacritinib	97.5%	—	—
Ripretinib	97.2%	—	—
Erdafitinib	96.5%	—	—
Brigatinib	96.0%	—	—
Dasatinib	95.9%	—	—
Ponatinib	95.2%	—	—
Nintedanib	95.0%	—	—
Pralsetinib	94.4%	—	—
Cabozantinib	94.3%	—	—
Apatinib	93.9%	—	—
Selpercatinib	93.7%	—	—
Sorafenib	92.9%	—	—
Fostamatinib	92.7%	—	—
Nilotinib	92.6%	—	—
Imatinib	92.1%	—	—
Axitinib	91.9%	—	—
Umbralisib	91.5%	—	—
Quizartinib	91.4%	—	—
Regorafenib	89.8%	—	—
Sunitinib	89.3%	—	—
Fedratinib	89.2%	—	—
Gilteritinib	89.1%	—	—
Pazopanib	88.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 40.4ms